Phaseline

Companies › Nova Therapeutics

Nova Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CART-PSMA cells
CAR-T cell therapy targeting PSMA (prostate-specific membrane antigen)
PSMAPhase 1Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05656573CART-PSMA cellsPhase 1Prostate CancerOncologyDec 2025

From the company's SEC filings

Cash and short-term investments of $536m on 2025-12-31; operating cash flow positive

Targets

PSMA (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience Inovio Pharmaceuticals Curium US Beijing Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.